drugset / Trial / NCT05239923
COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
Completed
35 enrolled
DreamTec Research Limited
Middle East Cell and Gene Therapy · collabNational Institute of Genetic Engineering and Biotechnology · collab
NaSingle-groupOpen-labelBasic science
Summary
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
Timeline
- Start
- 2021-08-28
- Primary completion
- 2021-11-30
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bacillus subtilis | Vaccine | 1e+10 unknown | Oral |